UPCOMING SERIES: Deep Data Dive: Highlights From ASCO 2024 on the Treatment of High-Risk BCG-Unresponsive NMIBC

Trinity Bivalacqua, MD, PhD, announces an upcoming UroView series highlighting key information presented at ASCO 2024 surrounding treatment of high-risk BCG-unresponsive NMIBC.

Now Viewing

EP: 1.UPCOMING SERIES: Deep Data Dive: Highlights From ASCO 2024 on the Treatment of High-Risk BCG-Unresponsive NMIBC

Related Videos

Related Content

Advertisement

February 4th 2025

FDA Updates in Urology: January 2025

Patrick Campbell

A recap of the FDA submissions and regulatory decisions in urology from January 2025.

April 21st 2025

Introducing Pearls & Perspectives, with Amy Pearlman, MD!

Amy M. Pearlman, MD

Pearls & Perspectives, hosted by Amy Pearlman, MD, is the latest multimedia program from Urology Times.

December 14th 2022

Study finds only half of patients undergoing 24-hour urine tests receive complete testing

Hannah Clarke

“One of the goals of this study was to look at whether 24-hour urine testing in the VA population included all the important components of 24-hour urine panel testing,” says Ryan Hsi, MD, FACS.

January 14th 2025

Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges

Wayne Kuang, MD Steven Maislos, MD

Panelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life considerations to optimize patient outcomes.

October 19th 2022

Study finds inadequate patient education for scheduled urologic procedures

Hannah Clarke

Researchers at Albert Einstein College of Medicine found patients benefited from a pre-procedural interview to educate them about the risks, benefits, and alternatives to urologic treatments they were scheduled to receive.

February 2nd 2021

First European patient treated for urethral stricture with novel drug-coated balloon catheter

Jason M. Broderick

The Optilume drug-coated balloon catheter system was approved in the EU in September 2020 for the treatment of patients with urethral stricture.

Related Content

Advertisement

February 4th 2025

FDA Updates in Urology: January 2025

Patrick Campbell

A recap of the FDA submissions and regulatory decisions in urology from January 2025.

April 21st 2025

Introducing Pearls & Perspectives, with Amy Pearlman, MD!

Amy M. Pearlman, MD

Pearls & Perspectives, hosted by Amy Pearlman, MD, is the latest multimedia program from Urology Times.

December 14th 2022

Study finds only half of patients undergoing 24-hour urine tests receive complete testing

Hannah Clarke

“One of the goals of this study was to look at whether 24-hour urine testing in the VA population included all the important components of 24-hour urine panel testing,” says Ryan Hsi, MD, FACS.

January 14th 2025

Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges

Wayne Kuang, MD Steven Maislos, MD

Panelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life considerations to optimize patient outcomes.

October 19th 2022

Study finds inadequate patient education for scheduled urologic procedures

Hannah Clarke

Researchers at Albert Einstein College of Medicine found patients benefited from a pre-procedural interview to educate them about the risks, benefits, and alternatives to urologic treatments they were scheduled to receive.

February 2nd 2021

First European patient treated for urethral stricture with novel drug-coated balloon catheter

Jason M. Broderick

The Optilume drug-coated balloon catheter system was approved in the EU in September 2020 for the treatment of patients with urethral stricture.